Precigen Stock Earnings Reports

Precigen reported a strong commercial launch for PAPZIMEOS (first full quarter of availability) with Q1 2026 net product revenue of $21.6M versus $3.4M in Q4 2025, signaling rapid uptake. Key commercial drivers include broad FDA label with no prior-surgery restrictions, durable clinical efficacy (median follow-up ~3 years), ease of administration enabling adoption in both major centers and community practices, permanent J-code (effective April 1) simplifying reimbursement, and extensive payer coverage (estimated 297 million lives; >90% of U.S. insured lives). The company’s PAPZIMEOS patient hub has ~400 registered patients (25% coming from community settings), though many patients are treated outside the hub. Management expects continued acceleration into Q2 and highlighted upcoming clinical/regulatory milestones: an ASCO update on durability data next month, initiation of a pediatric trial in Q4 2026, ongoing redosing evaluations, and continued EMA review. Pipeline progress: PRGN-2009 (AdenoVerse backbone) is advancing in multiple Phase II trials in combination with pembrolizumab for HPV-16/18-driven cancers with data updates expected later in the year. Financials: total Q1 revenue $23.3M, operating loss $6M, net loss $7.9M ($0.02/share). Cash, cash equivalents and investments were $56.7M at quarter end; cash used in operations was $43.8M (including ~$13M one-time outflows). Management reiterated that available cash plus expected PAPZIMEOS receivable collections are forecast to fund operations to cash-flow breakeven by end of 2026 and they do not currently plan to access capital markets. Next investor milestones: Q2 commercial results (August), ASCO durability update (next month), redosing and pediatric trial progress, and later-year PRGN-2009 updates.